Oruka Therapeutics Inc <ORKA.OQ> expected to post a loss of 68 cents a share - Earnings Preview
Oruka Therapeutics Inc ORKA.OQ ORKA.O is expected to report resultson January 30 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Oruka Therapeutics Inc is for a loss of 68 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Oruka Therapeutics Inc is $42.50, above its last closing price of $11.44.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.53 | -0.40 | -1.46 | Missed | -263.3 |
2024 | |||||
| |||||
| |||||
|
This summary was machine generated January 28 at 21:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
Warren Buffett Q2 2025 13F Analysis: Betting on UnitedHealth Again After 14 Years
TradingKey - In Q2 2025, the value of Berkshire Hathaway’s investment portfolio declined from $259.8 billion in Q1 to $257.5 billion, a decrease of 0.89%. Analysis indicates that this drop is primarily driven by a net capital outflow of 0.78%. The outflow may be linked to changing market conditions
Understanding the Fed’s Overnight Reverse Repo(RRP), What Is the Relationship Between QT and Debt Ceiling
TradingKey - As the U.S. enters a new rate cycle, the quantitative tightening (QT)—initially launched to reduce the Federal Reserve’s bloated balance sheet following the COVID-19 pandemic—is also nearing its conclusion. A key metric in gauging when to end QT is the scale of the Fed’s ON RRP...
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing.
U.S. July CPI Commentary: Obstacles Cleared, Where Will U.S. Stocks Go Next?
TradingKey - On 12 August 2025, the United States released its Consumer Price Index (CPI) data for July. In terms of headline inflation, the CPI rose by 2.7% year-on-year in the month, slightly lower than the expected 2.8%. However, core CPI climbed 3.1% year-on-year, edging past the projected 3.0%.
